FY2025 Earnings Forecast for CRBU Issued By Leerink Partnrs

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Stock analysts at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for Caribou Biosciences in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($1.77) for the year, down from their prior estimate of ($1.64). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. Leerink Partnrs also issued estimates for Caribou Biosciences’ FY2026 earnings at ($1.84) EPS, FY2027 earnings at ($1.83) EPS, FY2028 earnings at ($0.54) EPS and FY2029 earnings at $0.28 EPS.

Other equities analysts have also issued reports about the company. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Caribou Biosciences in a report on Friday, November 15th. Bank of America cut their price target on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, Citigroup dropped their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 26th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $10.33.

Caribou Biosciences Price Performance

Caribou Biosciences stock opened at $1.52 on Friday. The firm has a 50 day moving average price of $1.84 and a 200-day moving average price of $1.99. Caribou Biosciences has a twelve month low of $1.47 and a twelve month high of $8.33.

Caribou Biosciences (NASDAQ:CRBU) last released its earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. The company had revenue of $2.02 million for the quarter, compared to analysts’ expectations of $3.37 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%.

Institutional Investors Weigh In On Caribou Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Erste Asset Management GmbH purchased a new position in Caribou Biosciences during the third quarter valued at approximately $28,000. AQR Capital Management LLC bought a new position in Caribou Biosciences in the 2nd quarter valued at $30,000. China Universal Asset Management Co. Ltd. grew its position in shares of Caribou Biosciences by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,380 shares of the company’s stock valued at $34,000 after purchasing an additional 6,768 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Caribou Biosciences in the third quarter worth $43,000. Finally, Point72 DIFC Ltd increased its holdings in shares of Caribou Biosciences by 389.4% in the second quarter. Point72 DIFC Ltd now owns 30,157 shares of the company’s stock worth $49,000 after purchasing an additional 23,995 shares during the period. 77.51% of the stock is currently owned by institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.